A mid-size pharmaceutical company partnered with Herspiegel to establish a standing council of 30 patient advocates. This long-term engagement infused patient insights into strategic planning, enhancing relevance and trust across key functions. Read here.
We helped our client communicate key information about their portfolio and technology to help resonate with investors and support funding efforts. Read case study here.
We helped a client’s brand team improve patient adherence by mapping their access journey and identifying barriers and facilitators to patient access. Read the case study.
We helped a client’s brand team improve patient adherence by mapping their access journey and identifying barriers and facilitators to patient access. Read the case study.
Our client was approaching the launch of a new product for treatment of a mental health disorder. Despite promising trial data, successful adoption of their therapy would be challenging for a number of reasons. Read the case study.
Discover how we assisted our client in positioning their therapy for optimal impact in the evolving landscape of steroid reduction and global treatment strategies.
Explore how we analyzed and refined our client's drug positioning across multiple indications to ensure market alignment and strategic coherence. Read the case study.
Our client aimed to apply a proven molecule to a new neurological disorder. We helped create a compelling narrative and cost-effective strategy to boost ROI. Read the case study.
Learn how we guided our client through early-stage clinical trials and competitive pressures to craft a compelling scientific narrative. Read the case study.
Learn how we navigated the challenges of launching a novel treatment in a rare hematologic disease to position our client's drug as a potential new standard of care. Read the full case study.
We helped our major pharmaceutical client equip it organization to offer value-based contracts to support access for a new specialty drug. Read the case study.
Discover how our tailored reimbursement strategy propelled a small biotech's innovative ophthalmic product to exceed launch forecasts by 60% in patient treatment.
We partnered with our client to establish a narrative that increased availability results in improvements in health outcomes and downstream cost savings. Read the case study.
We helped a client’s new product team plan their US and EU access strategies for a novel compound with potential in both rare and more common respiratory conditions. Read the case study.
We helped a clinical-stage genetic medicine company enhance their manuscript and figures to meet the high standards of a top scientific journal. Discover how our targeted narrative refinement and figure enhancement led to their research being featured in a prestigious journal with an impact factor of 4.6.
A prominent pharmaceutical company launching its first to market gene therapy in a rare disease was seeking to enhance its market position and reimbursement approach.
A mid-sized global pharmaceutical organization entered a co-commercialization agreement with a top-10 pharmaceutical organization to launch its first product in oncology.
Support programs have the power to drive patients to start, stay and succeed on therapy. These programs and the best practices that drive patient experience and access are critical to success.
A global pharmaceutical company worked with us to plan their European Union (EU) access strategy for a novel oncolytic drug based on a new formulation. Read the case study.
Our client, a mid-sized biopharmaceutical company, aimed to introduce a new asset into the highly competitive Parkinson's disease category. Read the case study.
Our biotech client was facing the challenge of introducing a new competitor into the market while simultaneously gaining a deeper understanding of their disease state. To navigate this complex scenario, they needed a strategic document that would serve as the foundation for both internal and external communications.
Our client, a leading biopharmaceutical company, sought to embark on a clinical development program within a new therapeutic area in the rare disease space. Read the case study.
